We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+4.91%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.3B
AUM Growth
-$16.8M
(-0.32%)
Cap. Flow
-$266M
Cap. Flow
% of AUM
-5.01%
Top 10 Holdings %
Top 10 Hldgs %
22.18%
Holding
297
New
35
Increased
74
Reduced
86
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$60.5M |
| 2 |
S&P Global
SPGI
|
+$52.3M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$41.3M |
| 4 |
AGN
Allergan plc
AGN
|
+$38.2M |
| 5 |
LVNTA
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
|
+$37.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$98.3M |
| 2 |
Eli Lilly
LLY
|
+$54.1M |
| 3 |
Apple
AAPL
|
+$51.2M |
| 4 |
Fidelity National Information Services
FIS
|
+$42.9M |
| 5 |
Stryker
SYK
|
+$40.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Financials | 21.66% |
| 3 | Technology | 21.39% |
| 4 | Communication Services | 9.45% |
| 5 | Consumer Discretionary | 5.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TMUSP
176
DELISTED
T-Mobile US, Inc.5.50% Mandatory Convertible Preferred Stock, Series A
TMUSP
| $4.14M | 0.08% |
56,500
-163,500
| -74% | -$11.5M |
|
177
Amgen
AMGN
$203B
| $4.09M | 0.08% |
26,874
+2,845
| +12% | +$442K |
|
|
TSRO
178
DELISTED
TESARO, Inc.
TSRO
| $3.96M | 0.07% |
47,118
-152,882
| -76% | -$6.82M |
|
179
Hecla Mining
HL
$10.2B
| $3.8M | 0.07% |
770,000
+220,000
| +40% | +$889K |
|
180
Gilead Sciences
GILD
$161B
| $3.79M | 0.07% |
45,409
-429,643
| -90% | -$38.1M |
|
|
MON
181
DELISTED
Monsanto Co
MON
| $3.76M | 0.07% |
+36,354
| New | +$3.6M |
|
182
Main Street Capital
MAIN
$4.97B
| $3.7M | 0.07% |
112,500
| – | – |
|
|
AUY
183
DELISTED
Yamana Gold, Inc.
AUY
| $3.64M | 0.07% |
+697,000
| New | +$3.13M |
|
184
Healthpeak Properties
DOC
$15.4B
| $3.54M | 0.07% |
109,800
+54,900
| +100% | +$1.7M |
|
|
OAK
185
DELISTED
OAKTREE CAPITAL GROUP, LLC
OAK
| $3.47M | 0.07% |
77,500
| – | – |
|
|
NGD
186
DELISTED
New Gold Inc
NGD
| $3.3M | 0.06% |
+762,948
| New | +$3.22M |
|
187
SPS Commerce
SPSC
$2.25B
| $3.29M | 0.06% |
+108,664
| New | +$2.81M |
|
|
VTAE
188
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| $3.24M | 0.06% |
300,000
+190,000
| +173% | +$1.62M |
|
189
Rapid7
RPD
$634M
| $3.2M | 0.06% |
+254,844
| New | +$3.23M |
|
|
ICPT
190
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $3.12M | 0.06% |
+21,869
| New | +$3.19M |
|
|
MPT
191
Medical Properties Trust
MPT
$2.89B
| $3.04M | 0.06% |
200,000
| – | – |
|
192
Check Point Software Technologies
CHKP
$13.3B
| $3.03M | 0.06% |
+38,000
| New | +$3.18M |
|
|
PPLI
193
People Inc
PPLI
$3.1B
| $3.01M | 0.06% |
299,455
-65,466
| -18% | -$606K |
|
194
Alamos Gold
AGI
$12.4B
| $2.72M | 0.05% |
+325,000
| New | +$2.22M |
|
|
SIVB
195
DELISTED
SVB Financial Group
SIVB
| $2.59M | 0.05% |
27,192
-2,709
| -9% | -$277K |
|
196
Vertex Pharmaceuticals
VRTX
$121B
| $2.55M | 0.05% |
29,681
+16,768
| +130% | +$1.45M |
|
197
Booking.com
BKNG
$138B
| $2.36M | 0.04% |
47,225
-33,750
| -42% | -$1.75M |
|
|
WBMD
198
DELISTED
WebMD Health Corp.
WBMD
| $2.35M | 0.04% |
+40,400
| New | +$2.53M |
|
199
Moody's
MCO
$81.7B
| $2.27M | 0.04% |
+24,278
| New | +$2.35M |
|
200
Supernus Pharmaceuticals
SUPN
$2.68B
| $2.25M | 0.04% |
110,525
-11,561
| -9% | -$205K |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Polar Capital held 297 positions worth $5.3B, down 0.32% from $5.32B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Polar Capital withdrew a net $266M in Q2 2016, closing 35 positions and reducing 86 holdings. Its most notable exit was Stryker, an estimated $40.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Financials and Technology.
Against the trend, Polar Capital opened a new position in S&P Global worth $52.2M.
- Polar Capital's largest Q2 2016 buy was S&P Global: 487,049 shares worth $52.2M.
- Polar Capital added most to Pfizer in Q2 2016, an estimated $60.5M increase.
- Polar Capital's biggest Q2 2016 reduction was Johnson & Johnson, cutting an estimated $98.3M.
- Polar Capital fully exited Stryker in Q2 2016, selling an estimated $40.2M.
- Polar Capital's ten largest holdings make up 22% of its $5.3B portfolio in Q2 2016.
- Polar Capital opened 35 new positions and closed 35 in Q2 2016.
- Polar Capital's portfolio value fell 0.32% quarter-over-quarter to $5.3B.
Based on Polar Capital's 13F filing for Q2 2016, filed 15 Aug 2016.